Low-risk thyroid carcinoma: When is the treatment worse than the disease?

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 1, 2009, Pages 5-7

  Potenza, Matthew ^a   Mechanick, Jeffrey I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; ECHOGRAPHY; EDITORIAL; HUMAN; INCIDENCE; LARYNGOSCOPY; METASTASIS; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIALOADENITIS; THYROID CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID PAPILLARY MICROCARCINOMA; THYROIDECTOMY;

EID: 69549087579     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.4.1.5     Document Type: Editorial

References (24)

1. Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology 181(3), 683-687 (1991).
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295(18), 2164-2167 (2006).
3. Kang HW, No JH, Chung JH et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14(1), 29-33 (2004).
4. Frates MC, Benson CB, Doubilet PM et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J. Clin. Endocrinol. Metab. 91(9), 3411-3417 (2006).
5. Mazzaferri EL. Management of a solitary thyroid nodule. N. Engl. J. Med. 328(8), 553-559 (1993).
6. Shaha AR, Tuttle RM, Shah JP. Papillary microcarcinoma of the thyroid. J. Surg. Oncol. 95(7), 532-533 (2007).
7. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 71(2), 414-424 (1990).
8. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83(12), 2638-2648 (1998).
9. Mazzaferri EL. Managing small thyroid cancers. JAMA 295(18), 2179-2182 (2006).
10. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2), 109-142 (2006).
11. Fliegelman LJ, Genden EM, Brandwein M, Mechanick J, Urken ML. Significance and management of thyroid lesions in lymph nodes as an incidental finding during neck dissection. Head Neck 23(10), 885-891 (2001).
12. Antonaci A, Anello A, Aucello A et al. Microcarcinoma and incidental carcinoma of the thyroid in a clinical series: clinical behaviour and surgical management. Clin. Ter. 157(3), 225-229 (2006).
13. Cappelli C, Castellano M, Braga M et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J. Surg. Oncol. 95(7), 555-560 (2007).
14. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 56(3), 171-196 (1977).
15. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J. Surg. Oncol. 94(8), 692-700 (2006).
16. Sawka AM, Brierley JD, Tsang RW et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am. 37(2), 457-480 (2008).
17. Mazzaferri E. A randomized trial of remnant ablation - in search of an impossible dream? J. Clin. Endocrinol. Metab. 89(8), 3662-3664 (2004).
18. Ito Y, Uruno T Nakano K et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13(4), 381-387 (2003).
19. Tuttle RM, Leboeuf R, Robbins RJ et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med. 47(10), 1587-1591 (2006).
20. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br. J. Cancer 89(9), 1638-1644 (2003).
21. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr. Pract. 13(5), 498-512 (2007).
22. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med. 352(23), 2406-2412 (2005).
23. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab. 19(4), 138-145 (2008).
24. Mechanick JI, Carpi A. Thyroid cancer: the impact of emerging technologies on clinical practice guidelines. Biomed. Pharmacother. 62(8), 554-558 (2008).